NO20043563L - Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon - Google Patents

Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon

Info

Publication number
NO20043563L
NO20043563L NO20043563A NO20043563A NO20043563L NO 20043563 L NO20043563 L NO 20043563L NO 20043563 A NO20043563 A NO 20043563A NO 20043563 A NO20043563 A NO 20043563A NO 20043563 L NO20043563 L NO 20043563L
Authority
NO
Norway
Prior art keywords
beta2
inhibitors
alpha
cell adhesion
mediated cell
Prior art date
Application number
NO20043563A
Other languages
English (en)
Norwegian (no)
Inventor
Masatoshi Kakushima
Takayuki Kawaguchi
Toshiyuki Kume
Ila Sircar
Marshall Morningstar
Hidefumi Kaji
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of NO20043563L publication Critical patent/NO20043563L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
NO20043563A 2002-02-07 2004-08-26 Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon NO20043563L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35430902P 2002-02-07 2002-02-07
PCT/US2003/003449 WO2003066636A1 (en) 2002-02-07 2003-02-06 Inhibitors of alpha l beta 2 integrin mediated cell adhesion

Publications (1)

Publication Number Publication Date
NO20043563L true NO20043563L (no) 2004-11-01

Family

ID=27734354

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043563A NO20043563L (no) 2002-02-07 2004-08-26 Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon

Country Status (23)

Country Link
US (1) US7375128B2 (ru)
EP (1) EP1472257B1 (ru)
JP (1) JP2005517016A (ru)
KR (1) KR100625379B1 (ru)
CN (1) CN1301255C (ru)
AR (1) AR040068A1 (ru)
AT (1) ATE411995T1 (ru)
AU (1) AU2003210862B2 (ru)
BR (1) BR0307521A (ru)
CA (1) CA2474748A1 (ru)
CO (1) CO5601028A2 (ru)
DE (1) DE60324250D1 (ru)
EC (1) ECSP045222A (ru)
MX (1) MXPA04007643A (ru)
MY (1) MY137878A (ru)
NO (1) NO20043563L (ru)
NZ (1) NZ534208A (ru)
PE (1) PE20030899A1 (ru)
PL (1) PL372328A1 (ru)
RU (1) RU2315768C2 (ru)
TW (1) TW200303200A (ru)
WO (1) WO2003066636A1 (ru)
ZA (1) ZA200405647B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
EP1937685A1 (en) * 2005-10-06 2008-07-02 Novartis AG Tetrahydro-pyrrolizinone compounds as lfa-i mediators
CN101638429B (zh) * 2009-08-28 2012-01-25 南方医科大学 一种特异性识别细胞表面整合素α3β1的小分子肽
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
EP3969066A4 (en) * 2019-05-16 2023-10-04 Dispensing Dynamics International, Inc. PERFUME DISPENSERS AND METHODS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643748A1 (de) 1986-12-20 1988-06-30 Hoechst Ag Bicylische imide, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
PL336580A1 (en) 1997-03-03 2000-07-03 Boehringer Ingelheim Pharma Fine-molecular compounds useful in treating inflammatory diseases
WO1998058947A1 (en) 1997-06-25 1998-12-30 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
KR100496940B1 (ko) * 1999-10-20 2005-06-23 다나베 세이야꾸 가부시키가이샤 αＬβ2 개재된 세포 접착 억제제

Also Published As

Publication number Publication date
NZ534208A (en) 2005-12-23
RU2315768C2 (ru) 2008-01-27
US20050171174A1 (en) 2005-08-04
AR040068A1 (es) 2005-03-16
TW200303200A (en) 2003-09-01
CO5601028A2 (es) 2006-01-31
ATE411995T1 (de) 2008-11-15
AU2003210862B2 (en) 2006-10-26
KR100625379B1 (ko) 2006-09-20
ECSP045222A (es) 2006-04-19
BR0307521A (pt) 2004-12-28
WO2003066636A1 (en) 2003-08-14
DE60324250D1 (de) 2008-12-04
RU2004123219A (ru) 2006-02-10
CA2474748A1 (en) 2003-08-14
CN1301255C (zh) 2007-02-21
EP1472257A1 (en) 2004-11-03
MXPA04007643A (es) 2005-06-08
CN1628116A (zh) 2005-06-15
ZA200405647B (en) 2005-07-15
EP1472257B1 (en) 2008-10-22
PL372328A1 (en) 2005-07-11
PE20030899A1 (es) 2003-10-25
KR20040091625A (ko) 2004-10-28
US7375128B2 (en) 2008-05-20
AU2003210862A1 (en) 2003-09-02
JP2005517016A (ja) 2005-06-09
MY137878A (en) 2009-03-31

Similar Documents

Publication Publication Date Title
NO20030885L (no) Inhibitorer av <alfa>4 styrt celleadhesjon
CY2015015I1 (el) Παραγωγη τιακουμυκινης
DK1505963T3 (da) Hepatitis C-inhibitorer
DK1572670T3 (da) 5-substitueret-pyrazin eller -pyridin-glucokinaseaktivatorer
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
DE60300604D1 (de) Druckempfindliches Klebeband
NO20043645L (no) Sykloalkylinhibitorer av kaliumkanal-funksjon
DK1501508T3 (da) Inhibitorer af histondeatylase
NO20052676D0 (no) Polymorfer av bicifadin-saltsyre
ITTO20030629A1 (it) Procedimento di realizzazione di collegamenti ad
NO20044916L (no) Preparater av sulfinylacetamid
DE50303155D1 (de) Dichtring
DE50305444D1 (de) Haftklebeartikel
NO20034955L (no) Korrosjonsinhibitor
NO20043563L (no) Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon
DE60323571D1 (de) Wasseraktivierbarer Klebstoff
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
NO20031320D0 (no) System for klassifisering av havbunnsujevnhet
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
AU2003280382A8 (en) Enzymatic polymerisation of miniemulsions
NO20013669L (no) Reverse hydroksamatinhibitorer av matriks metalloproteinaser
DE60307471D1 (de) Hemmung
FI20021414A (fi) Tiivisterakenne
DK1582783T3 (da) Tætningsbånd
ATA7862002A (de) Wasserauslaufbatterie

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application